ABSTRACT
Recently, the Food and Drug Administration approved the Wingspan stent system (Boston Scientific, Fremont, CA) under the Humanitarian Device Exemption Program for patients with symptomatic intracranial stenosis ≥ 50%,39 based on the results of the European Wingspan pilot study.39,40
Use of this system involves submaximal inflation of an angioplasty balloon, followed by deployment of the Wingspan stent, which is a self-expanding intracranial stent composed of nitinol with similar trackability but at least twice the outward radial strength of the Neuroform III stent (Boston Scientific).38
